nach oben

Current Heart Failure Reports

Erschienen in:

07.12.2023 | Review

Sex Differences in Circulating Biomarkers of Heart Failure

verfasst von: Roopa A. Rao, Anju Bhardwaj, Mrudula Munagala, Sonu Abraham, Sanjana Adig, Arden Shen, Eman Hamad

Erschienen in: Current Heart Failure Reports | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of RevSiew

Evidence is scaling up for sex differences in heart failure; however, clinical relevance of sex-specific differential thresholds for biomarkers is not clearly known. Current ambiguity warrants a further look into the sex-specific studies on cardiac biomarkers and may facilitate understanding of phenotypic presentations, clinical manifestations, and pathophysiologic pathway differences in men and women.

Recent Findings

Recent studies have confirmed the fact that females have differential threshold for biomarkers, with lower troponin and higher NT proBNP levels. Ambiguity continues to exist in the clinical relevance of ST-2, Galectin 3, and other biomarkers.

Novel biomarkers, proteomic biomarkers, and circulating micro RNAs with machine learning are actively being explored. Biomarkers in HFpEF patients with higher female representation are evolving. In recent clinical trials, sex-related difference in biomarkers is not seen despite therapeutic intervention being more effective in females compared to males.

Summary

Sex-related difference exists in the expression of biomarkers in health and in various disease states of heart failure. However, this differentiation has not effectively translated into the clinical practice in terms of diagnostic studies or prognostication. Active exploration to bridge the knowledge gap and novel technologies can shed more light in this area.

Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, Killian JM, Roger VL. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015;175(6):996–1004. https://doi.org/10.1001/jamainternmed.2015.0924.CrossRefPubMedPubMedCentral

• Stolfo D, Uijl A, Vedin O, Strömberg A, Faxén UL, Rosano GMC, Sinagra G, Dahlström U, Savarese G. Sex-based differences in heart failure across the ejection fraction spectrum: phenotyping, and prognostic and therapeutic implications. JACC Heart Fail. 2019;7(6):505–15. https://doi.org/10.1016/j.jchf.2019.03.011. (Erratum.In:JACCHeartFail.2020Apr;8(4):345-346).CrossRefPubMed

Lam CS, Carson PE, Anand IS, Rector TS, Kuskowski M, Komajda M, McKelvie RS, McMurray JJ, Zile MR, Massie BM, Kitzman DW. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2012;5(5):571–8. https://doi.org/10.1161/CIRCHEARTFAILURE.112.970061.CrossRefPubMedPubMedCentral

Regitz-Zagrosek V. Sex and gender differences in heart failure. Int J Heart Fail. 2020;2(3):157–81. https://doi.org/10.36628/ijhf.2020.0004.CrossRefPubMedPubMedCentral

Lau ES, Binek A, Parker SJ, Shah SH, Zanni MV, Van Eyk JE, Ho JE. Sexual dimorphism in cardiovascular biomarkers: clinical and research implications. Circ Res. 2022;130(4):578–92. https://doi.org/10.1161/CIRCRESAHA.121.319916.CrossRefPubMedPubMedCentral

Januzzi J. Natriuretic peptides as biomarkers in heart failure. J Investig Med. 2013;61(6):950–5. https://doi.org/10.2310/JIM.0b013e3182946b69.CrossRefPubMedPubMedCentral

Bhardwaj A, Januzzi JL. Natriuretic peptide guided management of acutely destabilized heart failure. Rationale and treatment algorithm. Critical Pathways in cardiology. 2009. https://doi.org/10.1097/HPC.0b013e3181c4a0c6.

Zile, et al. Prognostic value of brain natriuretic peptide vs history of heart failure hospitalization in a large real-world population. Clin Cardiol. 2020. https://doi.org/10.1002/clc.23468.CrossRefPubMedPubMedCentral

Januzzi JL Jr, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, Kim HN, Baggish AL, Weiner RB, Chen-Tournoux A, Marshall JE, Moore SA, Carlson WD, Lewis GD, Shin J, Sullivan D, Parks K, Wang TJ, Gregory SA, Uthamalingam S, Semigran MJ. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol. 2011;58(18):1881–9. https://doi.org/10.1016/j.jacc.2011.03.072.CrossRefPubMed

10.

Fradley MG, Larson MG, Cheng S, McCabe E, Coglianese E, Shah RV, Levy D, Vasan RS, Wang TJ. Reference limits for N-terminal-pro-B-type natriuretic peptide in healthy individuals (from the Framingham Heart Study). Am J Cardiol. 2011;108:1341–5. https://doi.org/10.1016/j.amjcard.2011.06.057.CrossRefPubMedPubMedCentral

11.

Chang AY, Abdullah SM, Jain T, Stanek HG, Das SR, McGuire DK, Auchus RJ, de Lemos JA. Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. J Am Coll Cardiol. 2007;49:109–16. https://doi.org/10.1016/j.jacc.2006.10.040.CrossRefPubMed

12.

Lew J, Sanghavi M, Ayers CR, et al. Sex-based differences in cardiometabolic biomarkers. Circulation. 2017;135:544–55. https://doi.org/10.1161/CIRCULATIONAHA.116.023005.CrossRefPubMedPubMedCentral

13.

Maffei S, Del Ry S, Prontera C, Clerico A. Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women. Clin Sci (Lond). 2001;101:447–53.CrossRefPubMed

14.

• Suthahar, et al. Sex-specific associations of cardiovascular risk factors and biomarkers with incident heart failure. J Am Coll Cardiol. 2020;76(12):1455–65. https://doi.org/10.1016/j.jacc.2020.07.044. This study assessed associations of individual biomarkers with incident heart failure and none of the biomarkers displayed a significant interaction with sex for heart failure outcome.

15.

Franke J, Lindmark A, Hochadel M, Zugck C, Koerner E, Keppler J, Ehlermann P, Winkler R, Zahn R, Katus HA, Senges J, Frankenstein L. Gender aspects in clinical presentation and prognostication of chronic heart failure according to NT-proBNP and the heart failure survival score. Clin Res Cardiol. 2015;104:334–41. https://doi.org/10.1007/s00392-014-0786-z.CrossRefPubMed

16.

Kim HL, Kim MA, Choi DJ, Han S, Jeon ES, Cho MC, Kim JJ, Yoo BS, Shin MS, Seong IW, Ahn Y, Kang SM, Kim YJ, Kim HS, Chae SC, Oh BH, Lee MM, Ryu KH. Korean Heart Failure Registry. Gender difference in the prognostic value of N-terminal pro-B type natriuretic peptide in patients with heart failure – a report from the Korean Heart Failure Registry (KorHF). Circ J. 2017;81:1329–36. https://doi.org/10.1253/circj.CJ-16-1345.CrossRefPubMed

17.

Magnussen C, Niiranen et al. Sex-specific epidemiology of heart failure risk and mortality in Europe: results from the BiomarCaRE consortium. JACC: Heart Failure. 2019, 204–213. https://doi.org/10.1016/j.jchf.2018.08.008.

18.

• Myhre PL, et al. Sex and race differences in n-terminal pro–B-type natriuretic peptide concentration and absolute risk of heart failure in the community. JAMA Cardiol. 2022;7(6):623–31. https://doi.org/10.1001/jamacardio.2022.0680. In this study, sex- and race-based differences in NT-proBNP was noted and absolute risk associated with a given value of NT-proBNP varied substantially by sex and race. Consideration of NT-proBNP values in the context of sex and race allows for more uniform prediction of absolute risk across important demographic subgroups.

19.

Januzzi JL, Filippatos G, Nieminen M, Gheorghiade M. Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: heart failure section. Eur Heart J. 2012;33:2265–71. https://doi.org/10.1093/eurheartj/ehs191.CrossRefPubMed

20.

Romiti GF, Cangemi R, Toriello F, Ruscio E, Sciomer S, Moscucci F, Vincenti M, Crescioli C, Proietti M, Basili S, Raparelli V. Sex-specific cut-offs for high-sensitivity cardiac troponin: is less more? Cardiovasc Ther. 2019;2019:1–12. https://doi.org/10.1155/2019/9546931.CrossRef

21.

Aimo, et al. Prognostic value of high-sensitivity troponin t in chronic heart failure: an individual patient data meta-analysis. Circulation. 2018;137(3):286–97. https://doi.org/10.1161/CIRCULATIONAHA.117.031560.CrossRefPubMed

22.

Evans JDW, Dobbin SJH, Pettit SJ, di Angelantonio E, Willeit P. High-sensitivity cardiac troponin and new-onset heart failure: a systematic review and meta-analysis of 67,063 patients with 4,165 incident heart failure events. JACC Heart Fail. 2018;6:187–97. https://doi.org/10.1016/j.jchf.2017.11.003.CrossRefPubMed

23.

Gohar A, Chong JPC, Liew OW, den Ruijter H, de Kleijn DPV, Sim D, Yeo DPS, Ong HY, Jaufeerally F, Leong GKT, Ling LH, Lam CSP, Richards AM. The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs reduced ejection fraction. Eur J Heart Fail. 2017;19:1638–47. https://doi.org/10.1002/ejhf.911.CrossRefPubMed

24.

Bhardwaj A, Januzzi JL. ST2: a novel biomarker for heart failure. Expert Rev Mol Diagn. 2010;10(4):459–64. https://doi.org/10.1586/erm.10.25.CrossRefPubMed

25.

Bayés-Genis A, González A, Lupón J. ST2 in heart failure. Circ Heart Fail. 2018;11:e005582. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005582.CrossRefPubMed

26.

Dieplinger B, Januzzi JL, Steinmair M, Gabriel C, Poelz W, Haltmayer M, Mueller T. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma – the Presage ST2 assay. Clin Chim Acta. 2009;409:33–40. https://doi.org/10.1016/j.cca.2009.08.010.CrossRefPubMed

27.

Meyer S, van der Meer P, van Deursen VM, Jaarsma T, van Veldhuisen DJ, van der Wal MHL, Hillege HL, Voors AA. Neurohormonal and clinical sex differences in heart failure. Eur Heart J. 2013;34:2538–47. https://doi.org/10.1093/eurheartj/eht152.CrossRefPubMed

28.

Anand IS, Rector TS, Kuskowski M, Snider J, Cohn JN. Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial. Circ Heart Fail. 2014;7:418–26. https://doi.org/10.1161/CIRCHEARTFAILURE.113.001036.CrossRefPubMed

29.

Coglianese EE, Larson MG, Vasan RS, Ho JE, Ghorbani A, McCabe EL, et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham heart study. Clin Chem. 2012;58:1673–81. https://doi.org/10.1373/clinchem.2012.192153.CrossRefPubMedPubMedCentral

30.

Dieplinger B, Egger M, Poelz W, Gabriel C, Haltmayer M, Mueller T. Soluble ST2 is not independently associated with androgen and estrogen status in healthy males and females. Clin Chem Lab Med. 2011;49:1515–8. https://doi.org/10.1515/CCLM.2011.239. Epub 2011 Jun 10 PMID: 21663467.CrossRefPubMed

31.

Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, André S, Crijns HJ, Gabius HJ, Maessen J, Pinto YM. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110(19):3121–8. https://doi.org/10.1161/01.CIR.0000147181.65298.4D.CrossRefPubMed

32.

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137–61. https://doi.org/10.1161/CIR.0000000000000509.CrossRefPubMed

33.

Chow SL, Maisel AS, Anand I, Bozkurt B, de Boer RA, Felker GM, Fonarow GC, Greenberg B, Januzzi JL Jr, Kiernan MS, Liu PP, Wang TJ, Yancy CW, Zile MR. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation. 2017;135(22):e1054–91. https://doi.org/10.1161/CIR.0000000000000490.CrossRefPubMed

34.

Pang J, Nguyen VT, Rhodes DH, Sullivan ME, Braunschweig C, Fantuzzi G. Relationship of galectin-3 with obesity, IL-6, and CRP in women. J Endocrinol Invest. 2016;39(12):1435–43. https://doi.org/10.1007/s40618-016-0515-8.CrossRefPubMed

35.

Lau ES, Liu E, Paniagua SM, Sarma AA, Zampierollo G, López B, Díez J, Wang TJ, Ho JE. Galectin-3 Inhibition with modified citrus pectin in hypertension. JACC Basic Transl Sci. 2021;6(1):12–21. https://doi.org/10.1016/j.jacbts.2020.10.006.CrossRefPubMedPubMedCentral

36.

Jagodzinski A, Havulinna AS, Appelbaum S, Zeller T, Jousilahti P, Skytte-Johanssen S, Hughes MF, Blankenberg S, Salomaa V. Predictive value of galectin-3 for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort. Int J Cardiol. 2015;1(192):33–9. https://doi.org/10.1016/j.ijcard.2015.05.040.CrossRef

37.

M Dekleva and others, Sex related difference in heart failure development in patients after first myocardial infarction; role of galectine-3, European Heart Journal, Volume 43, Issue Supplement_2, October 2022, ehac544.816, https://doi.org/10.1093/eurheartj/ehac544.816.

38.

Motiwala SR, Szymonifka J, Belcher A, Weiner RB, Baggish AL, Sluss P, Gaggin HK, Bhardwaj A, Januzzi JL. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail. 2013;15(10):1157–63. https://doi.org/10.1093/eurjhf/hft075.CrossRefPubMed

39.

Barcena de Arellano ML, Pozdniakova S, Kühl AA, Baczko I, Ladilov Y, Regitz-Zagrosek V. Sex differences in the aging human heart: gen sirtuins, pro-inflammatory shift and reduced anti-oxidative defense. Aging (Albany NY). 2019;11(7):1918–33. https://doi.org/10.18632/aging.101881.CrossRefPubMed

40.

Bracun V, van Essen B, Voors AA, van Veldhuisen DJ, Dickstein K, Zannad F, Metra M, Anker S, Samani NJ, Ponikowski P, Filippatos G, Cleland JGF, Lang CC, Ng LL, Shi C, de Wit S, Aboumsallem JP, Meijers WC, Klip IT, van der Meer P, de Boer RA. Insulin-like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence. ESC Heart Fail. 2022;9(6):4167–76. https://doi.org/10.1002/ehf2.14120.CrossRefPubMedPubMedCentral

41.

Zhang L, Smyth D, Al-Khalaf M, et al. Insulin-like growth factor-binding protein-7(IGFBP7) links senescence to heart failure. Nat Cardiovasc Res. 2022;1:1195–214. https://doi.org/10.1038/s44161-022-00181-y.CrossRef

42.

Motiwala SR, Szymonifka J, Belcher A, Weiner RB, Baggish AL, Gaggin HK, Bhardwaj A, Januzzi JL Jr. Measurement of novel biomarkers to predict chronic heart failure outcomes and left ventricular remodeling. J Cardiovasc Transl Res. 2014;7(2):250–61. https://doi.org/10.1007/s12265-013-9522-8.CrossRefPubMed

43.

Hage C, Bjerre M, Frystyk J, Gu HF, Brismar K, Donal E, Daubert JC, Linde C, Lund LH. Comparison of prognostic usefulness of serum insulin-like growth factor-binding protein 7 in patients with heart failure and preserved versus reduced left ventricular ejection fraction. Am J Cardiol. 2018;121(12):1558–66. https://doi.org/10.1016/j.amjcard.2018.02.041.CrossRefPubMed

44.

Gandhi PU, Gaggin HK, Redfield MM, Chen HH, Stevens SR, Anstrom KJ, Semigran MJ, Liu P, Januzzi JL Jr. Insulin-like growth factor-binding protein-7 as a biomarker of diastolic dysfunction and functional capacity in heart failure with preserved ejection fraction: results from the RELAX trial. JACC Heart Fail. 2016;4(11):860–9. https://doi.org/10.1016/j.jchf.2016.08.002.CrossRefPubMedPubMedCentral

45.

Gandhi PU, Gaggin HK, Sheftel AD, Belcher AM, Weiner RB, Baggish AL, Motiwala SR, Liu PP, Januzzi JL Jr. Prognostic usefulness of insulin-like growth factor-binding protein 7 in heart failure with reduced ejection fraction: a novel biomarker of myocardial diastolic function? Am J Cardiol. 2014;114(10):1543–9. https://doi.org/10.1016/j.amjcard.2014.08.018.CrossRefPubMed

46.

Adamson C, Welsh P, Docherty KF, de Boer RA, Diez M, Drożdż J, Dukát A, Inzucchi SE, Køber L, Kosiborod MN, Ljungman CEA, Martinez FA, Ponikowski P, Sabatine MS, Morrow DA, Lindholm D, Hammarstedt A, Boulton DW, Greasley PJ, Langkilde AM, Solomon SD, Sattar N, McMurray JJV, Jhund PS. IGFBP-7 and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF. JACC Heart Fail. 2023;11(3):291–304. https://doi.org/10.1016/j.jchf.2022.09.004.CrossRefPubMed

47.

Tan ES, Chan SP, Choi YC, Chris JP, Troughton R, Poppe K, Lund M, Devlin G, Doughty RN, Richards AM. Regional handling and prognostic performance of circulating insulin-like growth factor binding protein-7 in heart failure. JACC: Heart Failure. 2023;11(6):662–74. https://doi.org/10.1016/j.jchf.2023.01.016.CrossRefPubMed

48.

Meessen JMTA, Cesaroni G, Mureddu GF, Boccanelli A, Wienhues-Thelen UH, Kastner P, Ojeda-Fernandez L, Novelli D, Bazzoni G, Mangiavacchi M, Agabiti N, Masson S, StaszewskyL LR. PREDICTOR Investigators. IGFBP7 and GDF-15, but not P1NP, are associated with cardiac alterations and 10-year outcome in an elderly community-based study. BMC Cardiovasc Disord. 2021;21(1):328. https://doi.org/10.1186/s12872-021-02138-8.CrossRefPubMedPubMedCentral

49.

Das SR, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation. 2005;112:2163–8. https://doi.org/10.1161/CIRCULATIONAHA.105.555573.CrossRefPubMed

50.

Suthahar N, Meijers WC, Ho JE, Gansevoort RT, Voors AA, van der Meer P, Bakker SJL, Heymans S, van Empel V, Schroen B, van der Harst P, van Veldhuisen DJ, de Boer RA. Sex-specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population. Eur J Heart Fail. 2018;20(8):1205–14. https://doi.org/10.1002/ejhf.1209.CrossRefPubMed

51.

Cediel G, Codina P, Spitaleri G, Domingo M, Santiago-Vacas E, Lupón J, et al. Gender-related differences in heart failure biomarkers. Front Cardiovasc Med. 2021;7:617705. https://doi.org/10.3389/fcvm.2020.617705.CrossRefPubMedPubMedCentral

52.

Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, Coats AJS, Metra M, Mebazaa A, Ruschitzka F, Lainscak M, Filippatos G, Seferovic PM, Meijers WC, Bayes-Genis A, Mueller T, Richards M, Januzzi JL. Heart Failure Association of the European Society of Cardiology. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2021;21:715–31. https://doi.org/10.1002/ejhf.1494.CrossRef

53.

Suthahar N, Meems, et al. Sex-related differences in contemporary biomarkers for heart failure: a review. Eur J Heart Fail. 2020;22(5):775–88. https://doi.org/10.1002/ejhf.1771.CrossRefPubMed

54.

Ndumele CE, Coresh J, Lazo M, Hoogeveen RC, Blumenthal RS, Folsom AR, Selvin E, Ballantyne CM, Nambi V. Obesity, subclinical myocardial injury, and incident heart failure. JACC Heart Fail. 2014;2:600–7. https://doi.org/10.1016/j.jchf.2014.05.017.CrossRefPubMedPubMedCentral

55.

Arao K, Yoshikawa T, Isogai T, Imori Y, Mochizuki H, Sakata K, Takaoka Y, Yamaguchi T, Nagao K, Yamamoto T, Takayama M. A study of takotsubo syndrome over 9 years at the Tokyo Cardiovascular Care Unit Network Registry. J Cardiol. 2023;82(2):93–9. https://doi.org/10.1016/j.jjcc.2022.12.011.CrossRefPubMed

56.

Azibani F, Sliwa K. Peripartum cardiomyopathy: an update. Curr Heart Fail Rep. 2018;15(5):297–306. https://doi.org/10.1007/s11897-018-0404-x.CrossRefPubMedPubMedCentral

57.

Ersbøll AS, Goetze JP, Johansen M, Hauge MG, Sliwa K, Vejlstrup N, Gustafsson F, Damm P. Biomarkers and their relation to cardiac function late after peripartum cardiomyopathy. J Card Fail. 2021;27(2):168–75. https://doi.org/10.1016/j.cardfail.2021.01.002.CrossRefPubMed

58.

Wilcox NS, Rotz SJ, Mullen M, Song EJ, Ky Hamilton B, Moslehi J, Armenian SH, Wu JC, Rhee JW, Ky B. Sex-specific cardiovascular risks of cancer and its therapies. Circ Res. 2022;130(4):632–51. https://doi.org/10.1161/CIRCRESAHA.121.319901.CrossRefPubMedPubMedCentral

59.

Stone JR, Kanneganti R, Abbasi M, Akhtari M. Monitoring for chemotherapy-related cardiotoxicity in the form of left ventricular systolic dysfunction: a review of current recommendations. JCO Oncol Pract. 2021;17(5):228–36. https://doi.org/10.1200/OP.20.00924.CrossRefPubMed

60.

Demissei BG, Hubbard RA, Zhang L, Smith AM, Sheline K, McDonald C, Narayan V, Domchek SM, DeMichele A, Shah P, Clark AS, Fox K, Matro J, Bradbury AR, Knollman H, Getz KD, Armenian SH, Januzzi JL, Tang WHW, Liu P, Ky B. Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction. J Am Heart Assoc. 2020;9(2):e014708. https://doi.org/10.1161/JAHA.119.014708.CrossRefPubMedPubMedCentral

61.

Bayes-Genis A, Cediel G, Domingo M, et al. Biomarkers in heart failure with preserved ejection fraction. Card Fail Rev. 2022;8:e20. https://doi.org/10.15420/cfr.2021.37.CrossRefPubMedPubMedCentral

62.

Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation Circulation. 2002;105:595–601. https://doi.org/10.1161/hc0502.103010.CrossRefPubMed

63.

Faxén UL, Lund LH, Orsini N, et al. N-terminal pro-B-type natriuretic peptide in chronic heart failure: the impact of sex across the ejection fraction spectrum. Int J Cardiol. 2019;287:66–72. https://doi.org/10.1016/j.ijcard.2019.04.023.CrossRefPubMed

64.

• Cunningham JW, Vaduganathan M, Claggett BL, et al. Effects of sacubitril/valsartan on N-terminal pro-B-type natriuretic peptide in heart failure with preserved ejection fraction. JACC Heart Failure. 2020;8:372–81. https://doi.org/10.1016/j.jchf.2020.03.002. Baseline NT-proBNP predicted HF events and sacubitril/valsartan reduced NT-proBNP consistently in men and women and in patients with lower or higher EF.

65.

Januzzi JL, Myhre PL. The challenges of NT-proBNP Testing in HFpEF: shooting arrows in the wind. JACC: Heart Failure. 2020;8:382–5. https://doi.org/10.1016/j.jchf.2020.03.003.CrossRefPubMed

66.

Hopper I, Kotecha D, Chin KL, et al. Comorbidities in heart failure: are there gender differences? Curr Heart Fail Rep. 2016;13:1–12. https://doi.org/10.1007/s11897-016-0280-1.CrossRefPubMed

67.

Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. The Lancet. 2012;380:1387–95. https://doi.org/10.1016/S0140-6736(12)61227-6.CrossRef

68.

Gohar A, Chong JPC, Liew OW, et al. (2017) The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction. Eur J Heart Fail. 2017;19:1638–47. https://doi.org/10.1002/ejhf.911.CrossRefPubMed

69.

Morfino P, Aimo A, Castiglione V, et al. Biomarkers of HFpEF: natriuretic peptides, high-sensitivity troponins and beyond. J Cardiovasc Dev Dis 2022;9. https://doi.org/10.3390/jcdd9080256.

70.

Tromp J, Khan MAF, Klip IT, et al. Biomarker profiles in heart failure patients with preserved and reduced ejection fraction. J Am Heart Assoc. 2017;6:e003989. https://doi.org/10.1161/JAHA.116.003989.CrossRefPubMedPubMedCentral

71.

Watson CJ, Gallagher J, Wilkinson M, et al. Biomarker profiling for risk of future heart failure (HFpEF) development. J Transl Med. 2021;19:61. https://doi.org/10.1186/s12967-021-02735-3.CrossRefPubMedPubMedCentral

72.

Engeli S, Utz W, Haufe S, et al. Fatty acid binding protein 4 predicts left ventricular mass and longitudinal function in overweight and obese women. Heart. 2013;99:944–8. https://doi.org/10.1136/heartjnl-2013-303735.CrossRefPubMed

73.

Harada T, Sunaga H, Sorimachi H, et al. Pathophysiological role of fatty acid-binding protein 4 in Asian patients with heart failure and preserved ejection fraction. ESC Heart Fail. 2020;7:4256–66. https://doi.org/10.1002/ehf2.13071.CrossRefPubMedPubMedCentral

74.

Takvorian KS, Wang D, Courchesne P, et al. The association of protein biomarkers with incident heart failure with preserved and reduced ejection fraction. Circulation: Heart Failure. 2023;16:e009446. https://doi.org/10.1161/CIRCHEARTFAILURE.121.009446.CrossRefPubMed

75.

Chandramouli C, Ting TW, Tromp J, et al. Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction. Eur J Heart Failure. 2022;24:681–4. https://doi.org/10.1002/ejhf.2435.CrossRef

76.

Chirinos Julio A, Zhao L, Reese-Petersen Alexander L, et al. Endotrophin, a collagen VI formation–derived peptide, in heart failure. NEJM Evidence 2022;1:EVIDoa2200091. https://doi.org/10.1056/EVIDoa2200091.

77.

Alma LJ, Bokslag A, Maas AHEM, et al. Shared biomarkers between female diastolic heart failure and pre-eclampsia: a systematic review and meta-analysis. ESC Heart Failure. 2017;4:88–98. https://doi.org/10.1002/ehf2.12129.CrossRefPubMedPubMedCentral

78.

Chirinos JA, Orlenko A, Zhao L, et al. Multiple plasma biomarkers for risk stratification in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol. 2020;75:1281–95. https://doi.org/10.1016/j.jacc.2019.12.069.CrossRefPubMedPubMedCentral

79.

Florijn BW, Bijkerk R, van der Veer EP, van Zonneveld AJ. Gender and cardiovascular disease: are sex-biased microRNA networks a driving force behind heart failure with preserved ejection fraction in women? Cardiovasc Res. 2018;114(2):210–25. https://doi.org/10.1093/cvr/cvx223.CrossRefPubMed

80.

Woolley RJ, Ceelen D, Ouwerkerk W, Tromp J, Figarska SM, Anker SD, Dickstein K, Filippatos G, Zannad F, Metra M, Ng L, Samani N, van Veldhuisen DJ, Lang C, Lam CS, Voors AA. Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction. Eur J Heart Fail. 2021;23(6):983–91. https://doi.org/10.1002/ejhf.2144.CrossRefPubMed

81.

Kobayashi M, Huttin O, Magnusson M, et al. Machine learning-derived echocardiographic phenotypes predict heart failure incidence in asymptomatic individuals. J Am Coll Cardiol Img. 2022;15(2):193–208. https://doi.org/10.1016/j.jcmg.2021.07.004.CrossRef

Titel: Sex Differences in Circulating Biomarkers of Heart Failure
verfasst von: Roopa A. Rao
Anju Bhardwaj
Mrudula Munagala
Sonu Abraham
Sanjana Adig
Arden Shen
Eman Hamad
Publikationsdatum: 07.12.2023
Verlag: Springer US
Erschienen in: Current Heart Failure Reports / Ausgabe 1/2024
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI: https://doi.org/10.1007/s11897-023-00634-w

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Sex Differences in Circulating Biomarkers of Heart Failure

Abstract

Purpose of RevSiew

Recent Findings

Summary

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of RevSiew

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Rethinking the Impact and Management of Diabetes in Heart Failure Patients

Antiarrhythmic Treatment in Heart Failure

The Role of the Wearable Defibrillator in Heart Failure

Appetite and its Regulation: Are there Palatable Interventions for Heart Failure?

Correction to: Differentiating Cardiac Troponin Levels During Cardiac Myosin Inhibition or Cardiac Myosin Activation Treatments: Drug Effect or the Canary in the Coal Mine?

Implications of Sex Differences on the Treatment Effectiveness in Heart Failure with Reduced Ejection Fraction Related to Clinical Endpoints and Quality of Life

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie